Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 10/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.66 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.61 |
| ▸ | BTK | Q06187 | 6/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691113 | 0.93 | EGFR (0.67) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL12262344 | 0.89 | EGFR (0.57) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL692807 | 0.87 | EGFR (0.68) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL690536 | 0.84 | MAP2K7 (0.69) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL9017578 | 0.84 | TGM2 (1.00) | TGM2EGFRERBB2MEN1NPC1 | |
| SCHEMBL691538 | 0.82 | EGFR (0.79) | TGM2EGFRMAP2K7BTKJAK3 | |
| SCHEMBL12282888 | 0.81 | EGFR (0.54) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL27797644 | 0.81 | BTK (0.53) | TGM2EGFRERBB2MAP2K7BTK | |
| SCHEMBL28400978 | 0.81 | EGFR (0.75) | TGM2EGFRERBB2BTKJAK3 | |
| SCHEMBL30423295 | 0.81 | EGFR (0.75) | TGM2EGFRERBB2BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| CN-105367503-A | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS INC | 2016-03-02 | — | — | CN | disclosed |
| CN-101902911-B | Heteroaryl compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2214486-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TGM2 1812/4885EGFR 1981/4885ERBB2 918/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TGM2 1812/4885EGFR 1981/4885ERBB2 918/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TGM2 1812/4885EGFR 1981/4885ERBB2 918/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TGM2 1812/4885EGFR 1981/4885ERBB2 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.